FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014302337> ?p ?o ?g. }

• W2014302337 abstract "Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). Its benefits in multiple myeloma (MM) remain unclear. Here we report the inhibitory effects of cladribine on MM cell lines (U266, RPMI8226, MM1.S), and its therapeutic potential in combination with a specific inhibitor of the signal transducer and activator of transcription 3 (STAT3).MTS-based proliferation assays were used to determine cell viability in response to cladribine. Cell cycle progression was examined by flow cytometry analysis. Cells undergoing apoptosis were evaluated with Annexin V staining and a specific ELISA to quantitatively measure cytoplasmic histone-associated DNA fragments. Western blot analyses were performed to determine the protein expression levels and activation.Cladribine inhibited cell proliferation of MM cells in a dose-dependent manner, although the three MM cell lines exhibited a remarkably different responsiveness to cladribine. The IC50 of cladribine for U266, RPMI8226, or MM1.S cells was approximately 2.43, 0.75, or 0.18 μmol/L, respectively. Treatment with cladribine resulted in a significant G1 arrest in U266 and RPMI8226 cells, but only a minor increase in the G1 phase for MM1.S cells. Apoptosis assays with Annexin V-FITC/PI double staining indicated that cladribine induced apoptosis of U266 cells in a dose-dependent manner. Similar results were obtained with an apoptotic-ELISA showing that cladribine dramatically promoted MM1.S and RPMA8226 cells undergoing apoptosis. On the molecular level, cladribine induced PARP cleavage and activation of caspase-8 and caspase-3. Meanwhile, treatment with cladribine led to a remarkable reduction of the phosphorylated STAT3 (P-STAT3), but had little effect on STAT3 protein levels. The combinations of cladribine and a specific STAT3 inhibitor as compared to either agent alone significantly induced apoptosis in all three MM cell lines.Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3. Our data suggest that MM patients with the features of MM1.S cells may particularly benefit from cladribine monotherapy, whereas cladribine in combination with STAT3 inhibitor exerts a broader therapeutic potential against MM." @default.
• W2014302337 created "2016-06-24" @default.
• W2014302337 creator A5008152319 @default.
• W2014302337 creator A5013755620 @default.
• W2014302337 creator A5016058970 @default.
• W2014302337 creator A5048727442 @default.
• W2014302337 creator A5065426253 @default.
• W2014302337 creator A5090637113 @default.
• W2014302337 creator A5070682341 @default.
• W2014302337 date "2011-06-16" @default.
• W2014302337 modified "2023-09-25" @default.
• W2014302337 title "Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma" @default.
• W2014302337 cites W1548640328 @default.
• W2014302337 cites W1965880766 @default.
• W2014302337 cites W1968654699 @default.
• W2014302337 cites W1972244910 @default.
• W2014302337 cites W1978805491 @default.
• W2014302337 cites W1981752409 @default.
• W2014302337 cites W1983066514 @default.
• W2014302337 cites W1997961866 @default.
• W2014302337 cites W2007840001 @default.
• W2014302337 cites W2010552629 @default.
• W2014302337 cites W2012048337 @default.
• W2014302337 cites W2014198490 @default.
• W2014302337 cites W2014308548 @default.
• W2014302337 cites W2017290745 @default.
• W2014302337 cites W2024902576 @default.
• W2014302337 cites W2025938931 @default.
• W2014302337 cites W2039722337 @default.
• W2014302337 cites W2041869213 @default.
• W2014302337 cites W2045961347 @default.
• W2014302337 cites W2047098009 @default.
• W2014302337 cites W2051019115 @default.
• W2014302337 cites W2053119951 @default.
• W2014302337 cites W2056521217 @default.
• W2014302337 cites W2063355387 @default.
• W2014302337 cites W2074356752 @default.
• W2014302337 cites W2080476012 @default.
• W2014302337 cites W2092646816 @default.
• W2014302337 cites W2093221289 @default.
• W2014302337 cites W2106466834 @default.
• W2014302337 cites W2115128424 @default.
• W2014302337 cites W2118310862 @default.
• W2014302337 cites W2121638813 @default.
• W2014302337 cites W2132047377 @default.
• W2014302337 cites W2137648328 @default.
• W2014302337 cites W2140504081 @default.
• W2014302337 cites W2146483998 @default.
• W2014302337 cites W2157158866 @default.
• W2014302337 cites W2255194647 @default.
• W2014302337 cites W2551191294 @default.
• W2014302337 cites W2609515889 @default.
• W2014302337 cites W4248987137 @default.
• W2014302337 cites W4252035755 @default.
• W2014302337 doi "https://doi.org/10.1186/1471-2407-11-255" @default.
• W2014302337 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3141773" @default.
• W2014302337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21679466" @default.
• W2014302337 hasPublicationYear "2011" @default.
• W2014302337 type Work @default.
• W2014302337 sameAs 2014302337 @default.
• W2014302337 citedByCount "21" @default.
• W2014302337 countsByYear W20143023372012 @default.
• W2014302337 countsByYear W20143023372013 @default.
• W2014302337 countsByYear W20143023372014 @default.
• W2014302337 countsByYear W20143023372015 @default.
• W2014302337 countsByYear W20143023372017 @default.
• W2014302337 countsByYear W20143023372018 @default.
• W2014302337 countsByYear W20143023372020 @default.
• W2014302337 countsByYear W20143023372021 @default.
• W2014302337 crossrefType "journal-article" @default.
• W2014302337 hasAuthorship W2014302337A5008152319 @default.
• W2014302337 hasAuthorship W2014302337A5013755620 @default.
• W2014302337 hasAuthorship W2014302337A5016058970 @default.
• W2014302337 hasAuthorship W2014302337A5048727442 @default.
• W2014302337 hasAuthorship W2014302337A5065426253 @default.
• W2014302337 hasAuthorship W2014302337A5070682341 @default.
• W2014302337 hasAuthorship W2014302337A5090637113 @default.
• W2014302337 hasBestOaLocation W20143023371 @default.
• W2014302337 hasConcept C126322002 @default.
• W2014302337 hasConcept C153911025 @default.
• W2014302337 hasConcept C185592680 @default.
• W2014302337 hasConcept C190283241 @default.
• W2014302337 hasConcept C203014093 @default.
• W2014302337 hasConcept C2778461978 @default.
• W2014302337 hasConcept C2779200787 @default.
• W2014302337 hasConcept C2780483514 @default.
• W2014302337 hasConcept C29537977 @default.
• W2014302337 hasConcept C502942594 @default.
• W2014302337 hasConcept C54355233 @default.
• W2014302337 hasConcept C553184892 @default.
• W2014302337 hasConcept C55493867 @default.
• W2014302337 hasConcept C62112901 @default.
• W2014302337 hasConcept C71924100 @default.
• W2014302337 hasConcept C81885089 @default.
• W2014302337 hasConcept C86803240 @default.
• W2014302337 hasConcept C88634738 @default.
• W2014302337 hasConceptScore W2014302337C126322002 @default.
• W2014302337 hasConceptScore W2014302337C153911025 @default.
• W2014302337 hasConceptScore W2014302337C185592680 @default.
• W2014302337 hasConceptScore W2014302337C190283241 @default.

• next